McKesson Corporation (MCK)
S&P 500 Gains and Losses Today: McKesson Falls Amid Plans To Exit Canada Businesses
Major U.S. equities indexes were mixed as the latest ADP jobs data showed a smaller-than-expected jump in private payrolls in August.
Drug distributor McKesson forecasts Q2 profit below estimates
Drug distributor McKesson on Thursday forecast second-quarter profit below Wall Street estimates.
McKesson Corporation (MCK) Wells Fargo 2024 Healthcare Conference (Transcript)
McKesson Corporation (NYSE:MCK ) Wells Fargo 2024 Healthcare Conference September 5, 2024 8:45 AM ET Company Participants Britt Vitalone - Executive Vice President and Chief Financial Officer Conference Call Participants Stephen Baxter - Wells Fargo Stephen Baxter Good morning. I'm Steve Baxter, the Healthcare Services Analyst at Wells Fargo.
McKesson Corporation (MCK) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching McKesson (MCK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
McKesson (MCK) Upgraded to Buy: Here's Why
McKesson (MCK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Should Value Investors Buy McKesson (MCK) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Wall Street Analysts See McKesson (MCK) as a Buy: Should You Invest?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
MCK Stock's Uptrend Likely to Continue After Core Ventures Acquisition
McKesson's agreement to acquire a controlling interest will likely bring advanced treatments and improved care experiences to patients.
Drug distributor McKesson to buy controlling stake in Core Ventures for about $2.5 bln
Drug distributor McKesson said on Monday it would buy a controlling stake in community cancer center Florida Cancer Specialists & Research Institute's business and administrative services unit, Core Ventures, for $2.49 billion in cash.
McKesson to acquire controlling stake in Core Ventures for $2.49 billion in cash
McKesson Corp. MCK, -1.56% said Monday it has agreed to acquire a controlling stake in Community Oncology Revitalization Enterprise Ventures, LLC , or Core Ventures, a physician-owned community oncology practice to about $2.49 billion in cash. Once the deal closes, Core Ventures will become part of McKesson's oncology network.
McKesson (MCK) Stock Gains 18% YTD: What's Driving the Rally?
McKesson's (MCK) shares rally on the back of solid fundamentals. Increasing volumes of prescription and specialty drugs boost the top line.
McKesson Corporation (MCK) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to McKesson (MCK). This makes it worthwhile to examine what the stock has in store.
